As clinicians eagerly await the results of cardiovascular (CV) outcomes studies of novel Lp(a) lowering agents in development, leading lipid experts at this year’s European Atherosclerosis Congress (24-27 May, Athens, Greece) focused on the importance of managing conventional risk factors in today’s patients with elevated Lp(a). Other highlights included the potential of an Lp(a)-adjusted polygenic risk score to improve identification of individuals at high CV risk, and fresh insights into the impact of ethnicity on the relationship between Lp(a) and atherosclerotic cardiovascular disease. There were also early indications of the cost effectiveness of Lp(a) lowering therapy, and new data on the impact of unbound apo(a) on changes in cardiovascular and kidney biomarkers following treatment to block apo(a) binding to apoB.
Reports by Jenny Bryan
- Act now in patients with elevated Lp(a)
- Lp(a)-adjusted polygenic risk score improves MI prediction
- Lp(a)-ASCVD risk relationship may vary with ethnicity
- Novel Lp(a) lowering therapies predicted to be cost effective
- Increase in unbound apo(a) with muvalaplin not linked to cardiovascular or kidney biomarker changes
